Education
About Us
Working with TipRanks
Follow Us
Moderna (DE:0QF)
XETRA:0QF
0QF Stock Chart & Stats
Day’s Range― - ―
52-Week Range€24.26 - €156.54
Previous CloseN/A
Volume96.78K
Average Volume (3M)37.99K
Market Cap
$10.13B
Enterprise Value€9.73B
Total Cash (Recent Filing)-$1.06B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.22
Next Earnings
May 01, 2025EPS Estimate
-2.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.63
Shares Outstanding385,815,900
10 Day Avg. Volume28,910
30 Day Avg. Volume37,992
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.89
Price to Cash Flow (P/CF)3.80
P/FCF Ratio3.70
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.49
Enterprise Value/Ebitda-2.87
Forecast
1Y Price Target
€47.78Price Target Upside81.40% Upside
Rating ConsensusHold
Number of Analyst Covering18
---
Moderna News
PremiumStock Analysis & Ideas
Potential Stock Woe Ahead as Pfizer (PFE) Riles Donald Trump
---
Bulls Say, Bears Say
Bulls Say
Cost Reduction StrategyThe company expects a $1 billion reduction in cash costs from 2024 to 2025, which contributes to the goal of cash breakeven by 2028.
Pipeline ProspectsPotential approvals in 2025, as well as higher vaccination rates and improved competitive positioning, could provide upside to revenue guidance.
Bears Say
Patent LitigationGenevant and Arbutus are seeking monetary relief and injunctions against Spikevax and additional Moderna products that use the same LNP technology.
Product Launch ChallengesTwo new setbacks disclosed: the norovirus vaccine program is now on 'clinical hold' by FDA and the combo flu+COVID program will require Moderna to demonstrate vaccine efficacy of the stand-alone flu component before approval can occur.
Revenue DeclineModerna is aiming to enhance its pipeline to drive revenues to offset the fall in Spikevax sales, however these efforts have been too little too late, as total revenue has fallen >60% y/y in FY23 with no product immediately available to carry on driving revenues.
---
Options Prices
Currently, No data available
---
Ownership Overview
18.59% Insiders
19.87%
Mutual Funds
21.50% Other Institutional Investors
16.92% Public Companies and
Individual Investors
0QF FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was €24.26 and its highest was €156.54 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $10.13B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is May 01, 2025 which is in 29 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Feb 14, 2025. The company reported -€2.686 earnings per share for the quarter, missing the consensus estimate of -€2.474 by -€0.212.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Undervalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -2.85.
How many shares outstanding does Moderna have?
Moderna has 385,815,900 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -€2.686 in its last earnings report, missing expectations of -€2.474. Following the earnings report the stock price went up 7.197%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in DE:0QF
---
Moderna Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€47.78 (81.40% Upside)
€47.78 (81.40% Upside)
Blogger Sentiment
Bullish
DE:0QF Sentiment 68%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.28%
12-Months-Change
Fundamentals
Return on Equity
-28.77%
Trailing 12-Months
Asset Growth
-23.25%
Trailing 12-Months
Company Description
Moderna
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
---
0QF Company Deck
---
0QF Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Moderna's earnings call reflected a challenging year with significant revenue declines and net losses. However, the company demonstrated strong cost-saving measures and maintained a substantial cash position. Progress in the product pipeline and operational efficiency goals offer potential for future growth.Read More>---
0QF Revenue Breakdown
55.16% U.S.
26.36% Rest of World
18.48% Europe
---
0QF Stock 12 Month Forecast
Average Price Target
€47.78
▲(81.40% Upside)
Technical Analysis
Best Analysts Covering 0QF
1 Year
1 Year Success Rate
9/34 ratings generated profit
1 Year Average Return
-3.96%
reiterated a buy rating 2 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 26.47% of your transactions generating a profit, with an average return of -3.96% per trade.
---